Development of Three Different NK Cell Subpopulations during Immune Reconstitution after Pediatric Allogeneic Hematopoietic Stem Cell Transplantation: Prognostic Markers in GvHD and Viral Infections by Sabine Huenecke et al.
February 2017 | Volume 8 | Article 1091
Original research
published: 10 February 2017
doi: 10.3389/fimmu.2017.00109
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Gianfranco Pittari, 
Hamad Medical Corporation, Qatar
Reviewed by: 
Nicholas D. Huntington, 
Walter and Eliza Hall Institute of 
Medical Research, Australia  
Anne Caignard, 
Institut National de la Santé et de la 
Recherche Médicale, France
*Correspondence:
Sabine Huenecke  
sabine.huenecke@kgu.de
Specialty section: 
This article was submitted to 
Alloimmunity and Transplantation, 
a section of the journal 
Frontiers in Immunology
Received: 01 November 2016
Accepted: 23 January 2017
Published: 10 February 2017
Citation: 
Huenecke S, Cappel C, Esser R, 
Pfirrmann V, Salzmann-Manrique E, 
Betz S, Keitl E, Banisharif-Dehkordi J, 
Bakhtiar S, Königs C, Jarisch A, 
Soerensen J, Ullrich E, Klingebiel T, 
Bader P and Bremm M (2017) 
Development of Three Different NK 
Cell Subpopulations during Immune 
Reconstitution after Pediatric 
Allogeneic Hematopoietic Stem Cell 
Transplantation: Prognostic Markers 
in GvHD and Viral Infections. 
Front. Immunol. 8:109. 
doi: 10.3389/fimmu.2017.00109
Development of Three Different nK 
cell subpopulations during immune 
reconstitution after Pediatric 
allogeneic hematopoietic stem cell 
Transplantation: Prognostic Markers 
in gvhD and Viral infections
Sabine Huenecke1*, Claudia Cappel1, Ruth Esser2, Verena Pfirrmann1,  
Emilia Salzmann-Manrique1, Sibille Betz1, Eileen Keitl1, Julia Banisharif-Dehkordi1, 
Shahrzad Bakhtiar1, Christoph Königs1, Andrea Jarisch1, Jan Soerensen1, Evelyn Ullrich1,3, 
Thomas Klingebiel1, Peter Bader1 and Melanie Bremm1
1 Clinic for Pediatric and Adolescent Medicine, University Hospital, Frankfurt, Germany, 2 GMP Development Unit, Hannover 
Medical School, Institute of Cellular Therapeutics, Hannover, Germany, 3 LOEWE Center for Cell and Gene Therapy, Goethe 
University, Frankfurt, Germany
Natural killer (NK) cells play an important role following allogeneic hematopoietic stem 
cell transplantation (HSCT) exerting graft-versus-leukemia/tumor effect and mediating 
pathogen-specific immunity. Although NK cells are the first donor-derived lymphocytes 
reconstituting post-HSCT, their distribution of CD56++CD16− (CD56bright), CD56++CD16+ 
(CD56intermediate=int), and CD56+CD16++ (CD56dim) NK cells is explicitly divergent from 
healthy adults, but to some extent comparable to the NK cell development in early 
childhood. The proportion of CD56bright/CD56int/CD56dim changed from 15/8/78% in early 
childhood to 6/4/90% in adults, respectively. Within this study, we first compared the NK 
cell reconstitution post-HSCT to reference values of NK cell subpopulations of healthy 
children. Afterward, we investigated the reconstitution of NK cell subpopulations post-
HSCT in correlation to acute graft versus host disease (aGvHD) and chronic graft versus 
host disease (cGvHD) as well as to viral infections. Interestingly, after a HSCT follow-up 
phase of 12  months, the distribution of NK cell subpopulations largely matched the 
50th percentile of the reference range for healthy individuals. Patients suffering from 
aGvHD and cGvHD showed a delayed reconstitution of NK cells. Remarkably, within 
the first 2  months post-HSCT, patients suffering from aGvHD had significantly lower 
levels of CD56bright NK cells compared to patients without viral infection or without graft 
versus host disease (GvHD). Therefore, the amount of CD56bright NK cells might serve 
as an early prognostic factor for GvHD development. Furthermore, a prolonged and 
elevated peak in CD56int NK cells seemed to be characteristic for the chronification of 
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inTrODUcTiOn
The reconstitution of natural killer (NK) cells following allo-
geneic hematopoietic stem cell transplantation (HSCT) plays 
an important role in the response against residual malignant 
cells and the control of viral infections (1, 2). Independent 
of the graft source, NK cells typically regenerate within the 
first month following HSCT (3). However, there is an over-
representation of CD56brightCD16neg NK cells in the early phase 
post-HSCT compared to healthy individuals (4, 5), where NK 
cells are composed of about 90% CD56dimCD16++ and 10% 
CD56brightCD16− cells. Whereas CD56dimCD16++ NK cells medi-
ate cytotoxicity and antibody-dependent cellular cytotoxicity, 
the CD56brightCD16− subpopulation, which is mainly present in 
the early period post-HSCT, primarily secretes immunoregula-
tory cytokines. Presumably, the development from CD56bright to 
CD56dim NK cells corresponds to sequential steps of NK cell dif-
ferentiation (6). In most patients, the ratio between CD56bright 
and CD56dim NK cells normalizes within the first 6  months 
post-HSCT influenced by the patient’s age and events following 
HSCT. A correlation between the reconstitution of NK cells 
and overall survival was described by few studies emphasizing 
their essential role in the defense of infections when T cell 
immunity is mainly absent (7, 8). Furthermore, NK cells were 
successfully applied as immunotherapy for patients with high-
risk malignancies suffering from impending relapse following 
HSCT. In clinical studies, adoptively infused NK cells induced 
graft-versus-leukemia/tumor effect without concomitant 
severe graft versus host disease (GvHD) (9–11). In addition, 
recent studies ascribe GvHD reduction to NK cell function 
post-HSCT (12). In this work, we focused on the regeneration 
of CD56bright and CD56dim NK cells with a special regard on the 
population shifting between these subpopulations. We divided 
NK cells in three NK cell subpopulations. In the first step, we 
established reference values of CD56++CD16− (CD56bright), 
CD56++CD16+ (CD56int), and CD56+CD16++ (CD56dim) NK 
cells of healthy children and adolescents (n  =  174). These 
reference values were matched and compared to the NK cell 
reconstitution of patients, who did not suffer from any viral 
infection or GvHD and are still alive after allogenic stem cell 
transplantation. In the next step, we investigated the associa-
tions between the reconstitution of the three different NK cell 
subpopulations in regard to the occurrence of events such as 
acute graft versus host disease (aGvHD) or chronic graft versus 
host disease (cGvHD) and severe viral infections in the first 
year post-HSCT in contrast to a cohort of patients without 
severe events assumed as control group.
MaTerials anD MeThODs
reference cohort of children and 
adolescents
In this cross-sectional monocentric study (approval ethic com-
mittee Ref. No. 139/09), 174 donors (64 females and 110 males) 
were included. Residual peripheral blood samples of hemato-
logically healthy children aged 1 month to 18 years were analyzed 
(patients were hospitalized, e.g., for cleft lip and palate correction). 
Inclusion criteria involved no incidence of immunodeficiency or 
infection (defined as >2 severe infections/year, >8 infections/
year, persistent fungal infections, post-vaccinal complications, 
no evidence of acute bleeding, negative for CRP and normal 
leukocytes, lymphocytes, and neutrophil granulocytes).
Patients and grafts
The reconstitution of NK cells and their subpopulation CD56bright, 
CD56int, and CD56dim was analyzed in n = 74 patients (n = 25 
females and n = 49 males) transplanted from 2010 to 2016 (see 
Table  1). Indications for HSCT were high-risk acute lympho-
blastic leukemia (n =  51), acute myeloid leukemia (n =  12), 
and myelodysplastic syndrome (n =  11). Median age at HSCT 
was 10.4  years (range: 1.3–24.4  years). Grafts were received 
from matched family donors (MSD; n = 20), matched unrelated 
donors (MUD) (n = 39), and haploidentical mismatched family 
donors with <8/10 HLA matches (MMFD; n = 15). No significant 
differences in the occurrence of GvHD were available in the 
different donor groups (MSD: 6/20, MUD: 10/39, and MMFD: 
3/15). A second or third transplant was administered to n = 9 
and n = 2 patients, respectively, because of relapse after first or 
second HSCT. Stem cell sources consisted of (bone marrow; 
n = 48), unmanipulated PBSC (n = 11), and T cell-depleted PBSC 
(n = 15). Post-transplant aGvHD occurred in n = 31 patients with 
grades I (n = 9), II (n = 3), III (n = 16), and IV (n = 3), cGvHD 
in 22 patients. Severe viral infections occurred in 18 patients 
including primary infection or reactivation with cytomegalovirus 
(CMV) (n =  8), adenovirus (ADV) (n =  5), and Epstein–Barr 
virus (EBV) (n = 5).
study Design
This study was carried out in accordance with the Declaration of 
Helsinki and was approved by the Medical Ethics Committee of 
the Frankfurt University Hospital (Ref. No. #198/16). Peripheral 
blood was collected within the framework of a post-HSCT routine 
sampling for clinical follow-up from 2010 to 2016. In engrafted 
patients, samples were collected starting at day 15, within the first 
GvHD. In context of viral infection, a slightly lower CD56 and CD16 receptor expression 
followed by a considerable reduction in the absolute CD56dim NK cell numbers combined 
with reoccurrence of CD56int NK cells was observed. Our results suggest that a precise 
analysis of the reconstitution of NK cell subpopulations post-HSCT might indicate the 
occurrence of undesired events post-HSCT such as severe aGvHD.
Keywords: nK cells, immune reconstitution, cD56, cD16, allogeneic transplantation, children, reference values
TaBle 1 | Patient’s characteristics.
groups all agvhD cgvhD Viral 
infection
control 
group
Patients 74 19 22 (8) 18 23
Diagnosis
ALL 51 13 12 (4) 13 17
AML 12 3 3 (2) 5 3
MDS 11 3 7 (2) 0 3
age at hscT
Median (range) 10.4 
(1.3–24.4)
8.9  
(1.9–17.6)
9.4 
(1.3–18.2)
10.3 
(3.4–17.7)
12.1 
(2.3–24.4)
sex
Male 49 11 15 (6) 13 16
Female 25 8 7 (2) 5 7
Donor type
MSD 20 6 11 (4) 1 6
MUD 39 10 9 (2) 9 13
MMFD 15 3 2 (2) 8 4
stem cell source
BM 48 12 17 7 16
Unmanipulated PBSC 11 4 3 3 3
T cell depleted 15 3 2 8 4
gvhD
aGVHD 31 19 20 0 0
Grade I/II/III/IV 9/3/16/3 0/0/16/3 9/3/7/1 0/0/0/0 0/0/0/0
cGvHD 22 8 22 0 0
Viral infections
ADV/CMV/EBV 5/8/5 0/0/0 0/0/0 5/8/5 0/0/0
survival (%) 87 74 96 78 100
Follow-up (months)
Median (range) 35 
(3–105)
33 
(3–77)
43  
(6–92)
28 
(2–103)
48 
(24–105)
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; MDS, 
myelodysplastic syndrome; HSCT, hematopoietic stem cell transplantation; MSD, 
matched sibling donor; MUD, matched unrelated donor; MMFD, mismatched family 
donor; BM, bone marrow; PBSC, peripheral blood stem cells; GvHD, graft versus host 
disease; aGvHD, acute graft versus host disease; cGvHD, chronic graft versus host 
disease; ADV, adenovirus; CMV, cytomegalovirus; EBV, Epstein–Barr virus.
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year monthly, within the second year three monthly, and after-
ward every 6 months until 36 months post-HSCT, respectively. 
In total, n = 925 measurements of n = 74 patients were included 
in this analysis.
Depending on the occurrence of unexpected events such as 
aGvHD (only grades III and IV, grades I and II excluded), cGvHD, 
and severe viral infections, the study group was partitioned. The 
patient group without aGvHD/cGvHD or any viral infections was 
chosen for comparison as control group.
Patients showing a distinct CD56int population in a sufficient 
absolute amount post-HSCT were elected for more detailed 
analysis applying a 10-color flow cytometry.
assessment of nK cells and Their 
subpopulations
Natural killer cell subpopulations were analyzed on a FC500 
flow-cytometer (Beckman Coulter, Krefeld, Germany) 
applying a five-color panel to estimate CD3+ T cells, CD19+  
B cell, and CD3−CD56+ NK cells, including the differentiation 
into CD56++CD16−, CD56++CD16+, CD56+CD16++ NK cells, 
abbreviated as CD56bright, CD56int, and CD56dim NK cells, 
respectively. Absolute cell numbers were estimated from 
peripheral blood samples in a dual platform lyse-no-wash pro-
cedure as described previously (13). In brief, a tube of 100 µl 
EDTA-peripheral blood was labeled with CD45/CD56/CD19/
CD3 tetraCHROME (clones B3821F4A/N901/J3-119/UCHT1) 
multi-color mAb conjugated with FITC, phycoerythrin (PE), 
phycoerythrin texas red (ECD), and phycoerythrin-cyanine 5 
(PC5). CD16 phycoerythrin-cyanine 7 (PC7, clone: 6607118) 
was additionally added. For the measurement of T cells includ-
ing T helper and cytotoxic T cells, we applied the tetraCHROME 
multi-color reagent CD45/CD4/CD8/CD3 (clones B3821F4A/
SFCI12T4D11/SFCI21Thy2D3/UCHT1) conjugated with FITC, 
PE, ECD, and PC5. All reagents were acquired from Beckman 
Coulter Immutech (Marseille, France).
Differences in the expression profiles of CD56bright, CD56int, and 
CD56dim cells were analyzed applying two panels on a Navios™ 
10-color flow cytometer (Beckman Coulter, Krefeld, Germany). 
Panel 1: CD226 =  DNAM-1 (FITC; clone: KRA236), NKG2A 
(PE; clone: Z199), DUMP = CD3&CD14&CD19 (ECD; clones: 
UCHT1, RMO52, J3-119), CD117 (PC5.5; clone: 104D2D1), 
CD27 (PC7; clone: 1A4CD27), CD56 [allophycocyanin (APC); 
clone: N901], CD127 (APC-A700; clone: R34.34), CD16 (APC-
A750; clone: 3G8), CD57 [Pacific Blue (PB); clone: NC1], CD45 
[Krome Orange (KrO); clone: J.33]. Panel 2: CCR5 (FITC; 
clone: 2D7), killer cell immunoglobulin-like receptor (KIR) mix 
(CD158 + CD158b + CD158e1; clones: EB6B, GL183, Z27.3.7), 
DUMP = CD3 + CD14 + CD19 (ECD; clones: UCHT1, RMO52, 
J3-119), CD117 (PC5.5; clone: 104D2D1), CX3CR1 (PC7; clone: 
2A9-1), CD56 (APC; clone: N901), CD62L (APC-A700; clone: 
DREG56), CD16 (APC-A750; clone: 3G8), CCR7 (PB; clone: 
G043H7), and CD45 (KrO; clone: J.33). All antibodies were 
purchased from Beckman Coulter Immutech except CCR5 (BD 
Biosciences, Heidelberg, Germany) and CX3CR1 (Biolegend, 
San Diego, CA, USA). Staining was performed, using 100 µl of 
peripheral blood for each tube followed by 15  min of incuba-
tion at room temperature and erythrocyte lysis applying NH4Cl 
reagent (Beckman Coulter, Marseille, France).
Stained Cyto-Comp™ cells were applied to compensate the 
fluorescence overlap. The flow cytometer fluidic stability and 
the optical alignment were daily tested using Flow-Check™ 
Fluorospheres (Beckman Coulter, Krefeld, Germany). For verifi-
cation, Immunotrol cells (Beckman Coulter) were applied three 
times a day. Furthermore, we participate in an external quality 
assessment for the detection of T-, B-, and NK cells (INSTANT e. 
V.—provider for German round robin test, No 213).
Data evaluation was performed using Kaluza and CXP-
software (Beckman Coulter).
statistical analysis
Statistical analysis was performed using GraphPad Prism 6 
(GraphPad Software, San Diego, CA, USA). The NK subpopula-
tion reference values of healthy children and adolescents were 
calculated with non-linear exponential regression analysis 
FigUre 1 | reconstitution of cD56bright, cD56int, and cD56dim natural killer (nK) cells with respect to reference percentiles of healthy children. 
Reconstitution of CD56bright, CD56int, and CD56dim NK cells plotted into a graph showing the 10th, 90th (…., dotted line), and 50th (▬, solid line) percentile of NK cell 
reference values of healthy children (n = 174) as well as their underlying measurements (◼, gray squares). Measurements of stem cell transplanted patients without 
graft-versus-host disease or viral infections (n = 23; mean with SD) were plotted into the reference model (○, black rimmed circles) at 19 time points until 36 months 
after hematopoietic stem cell transplantation (HSCT). Time points were 15 days, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, 21, 14, 30, and 36 months after SCT. 
The CD56bright and CD56dim NK cells post-HSCT needed around 12 months to reach the distribution of healthy individuals NK cells. At that time point, the CD56bright, 
CD56int, and CD56dim NK cells met the 50th percentile of the reference range (a–c). CD56bright NK cells were elevated post-HSCT but already reached the reference 
range after 2 months (a). Intermediate NK cells matched the reference range directly after HSCT but showed a fast proliferation until 5 months followed by a decline 
until 12 months post-HSCT (B). CD56dim NK cells were underrepresented directly after HSCT, reaching the lower reference range after 8 months post-HSCT (c). 
The development of absolute cell counts of CD56bright, CD56int, and CD56dim NK cells is shown in subfigures (D–F).
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(equation: one-phase decay, least square fit; function: Y = (Y0 ‒  
Plateau)  ×  exp(‒  K  ×  X)  +  Plateau). Significant differences 
between groups were assessed by a non-paired two-tailed Mann–
Whitney U test. p-Values <0.05 were regarded as significant 
and are indicated as *p <  0.05, **p <  0.01, ***p <  0.001, and 
****p < 0.0001.
resUlTs
normalization of cD56bright to cD56dim  
ratio Post-hscT within the First Year 
Post-hscT
The distribution of NK cell subpopulations post-HSCT is 
divergent from healthy individuals showing a high proportion 
of CD56bright cells shifting toward CD56dim NK cells. To estimate 
the reconstitution time to a normal CD56bright, CD56int, and 
CD56dim NK cell distribution and absolute cell counts post-
HSCT, we first generated age-matched reference values of NK 
cell subpopulation frequencies and absolute NK cell counts for 
healthy children and adolescents (Figure S1 in Supplementary 
Material). Interestingly, the proportion of CD56bright, CD56int, and 
CD56dim in early childhood changed from 15, 8, and 78 to 6, 4, 
and 90% in adults, respectively. Subsequently, we matched the 
NK cell reconstitution of all patients of the control group without 
severe events (e.g., GvHD, infections) with the newly generated 
reference values (Figure 1). The frequency of CD56bright NK cells 
is elevated directly after HSCT but reaches the upper reference 
range following 2  months. However, the levels of CD56bright 
appear slightly increased remaining between the 50th and 90th 
percentile until 12 months post-HSCT (Figure 1A). Surprisingly, 
the percentage of CD56int cells matches the reference range 
within the first 2 months post-HSCT but increases starting from 
3  months exceeding the 90th percentile of the reference range 
following 5  months post-HSCT. After this period, the CD56int 
fraction declines and converges to the 50th percentile of the 
reference values 12 months after HSCT (Figure 1B). By contrast, 
the CD56dim fraction remains below the 10th percentile until 
8  months and reaches the 50th percentile of normal reference 
values after 12  months post-HSCT (Figure  1C). Comparable 
reconstitution profiles are also apparent for absolute values of 
CD56bright, CD56int, and CD56dim NK cells. However, absolute 
FigUre 2 | comparison of natural killer (nK) cell reconstitution in patients suffering from acute graft versus host disease (agvhD) versus patients 
without events. Regeneration of CD56bright, CD56int, and CD56dim NK cells in patients affected with severe aGvHD with grade III and IV (■, red squares, n = 19) and 
patients without events post-hematopoietic stem cell transplantation (HSCT) (□, green rimmed squares, n = 23) at time point of 15 days, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 
11, 12, 15, 18, 21, 14, 30, and 36 months after SCT. Especially, in the first 3 months, post-HSCT aGvHD patients showed significantly lower CD56bright NK cells in 
both percentage (a) (p < 0.0001) and absolute amounts (D) (p < 0.01). CD56int NK cells of aGvHD patients seem delayed in their development as patients without 
events show an increased intermediate population over a period of at least 18 months (B,e). Except in the beginning, CD56dim NK cell levels of GvHD patients 
remain below those of patients without events during the whole monitoring interval (c,F). Measurements were available at almost all time points, except for five 
patients of the aGvHD group who died 2, 3, 9, 9, and 18 months post-HSCT.
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values after HSCT seem to be lower than NK cells of healthy 
children (Figures 1D–F).
reconstitution of nK cells with  
regard to gvhD Development
Patients suffering from aGvHD with grade higher than III show 
significant differences in the reconstitution of NK cell subpopula-
tions compared to patients without any severe events post-HSCT. 
The median time of first symptoms of aGvHD was 22 days post-
HSCT (range: 13–84). Within the first, second, and third month 
68, 89, and 100% of the affected patients showed first signs of 
aGvHD, respectively. Patients without events show conspicuously 
higher frequency of CD56bright NK cells within the first 3 months 
following HSCT compared to patients suffering from aGvHD 
with the most significant difference already 15  days following 
engraftment (p < 0.0001; Figure 2A). This could also be shown 
for the absolute CD56bright NK cell amount 1 month after HSCT 
(p < 0.01; Figure 2D). This tendency was less pronounced when 
analyzing NK cells in patients with lower grades aGvHD (data not 
shown). Furthermore, the reconstitution of NK cell subpopula-
tions seems to be delayed in patients suffering from aGvHD. For 
the CD56int NK cell population, a displacement in time could be 
shown, which leads to a longer increase in CD56int frequency and 
absolute amount (Figures 2B,E). To reach the 50th percentile of 
normal reference values, patients with aGvHD need a prolonged 
reconstitution time taking at least two times longer compared to 
patients without events. Patients with lower GvHD grades were 
lying in between (data not shown). Even after 3 years of monitor-
ing, a trend toward higher frequency of CD56bright and CD56int 
NK cells concomitant with lower CD56dim was seen in patients 
suffering from severe aGvHD (not significant, Figures  2A–C). 
These differences in the NK cell development post-HSCT were 
also found evaluating the absolute amounts of NK cell subpopula-
tions (Figures 2D–F). Noteworthy, patients affected with aGvHD 
following HSCT also show a reduced absolute amount of CD56dim 
NK cells after 3 years post-HSCT (Figure 2F). Analyzing absolute 
NK cell count (including all three subgroups), we did not see a 
correlation between patients with and without aGvHD (Figure 
S2A in Supplementary Material). Analyzing cytotoxic T cells, we 
detected that patients reaching levels of cytotoxic T cells above 
1,500/μl within the first year post-HSCT developed in almost all 
cases an aGvHD (Figure S2B in Supplementary Material). But this 
fact was only true for less than 25% of the total aGvHD patient 
cohort. Furthermore, we evaluated the NK cell regeneration of 
FigUre 3 | natural killer (nK) cell reconstitution in patients suffering from chronic graft versus host disease (cgvhD). Development of CD56int NK cells 
of patients suffering from cGvHD after severe acute graft versus host disease (grade III or IV) is shown for frequency (a) and absolute count (B). Over a period of at 
least 18 months, a higher amount of CD56int NK cells for patients suffering from cGvHD (■, dark red squares, n = 8) was detectable compared to patients without 
severe events post-hematopoietic stem cell transplantation (□, green rimmed squares, n = 23).
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patients with primary aGvHD grade III or IV that became chronic. 
Thereby, we detected important differences in the development of 
NK cell subpopulations from CD56bright above CD56int to CD56dim 
NK cells. The development from CD56int to CD56dim NK cells is 
delayed for at least 2 years. Furthermore, patients with chronifica-
tion of aGvHD with grade >III have a markedly elevated CD56int 
frequency (Figure 3A), which is also clearly visible in absolute 
cell count of CD56int NK cells (Figure 3B).
receptor expression of cD56bright, cD56int, 
and cD56dim nK cells Post-hscT
As part of the patients had low absolute cell counts post-HSCT, 
a detailed phenotyping of the CD56bright, CD56int, and CD56dim 
NK cell populations was only possible for an elected cohort of 
patients. To get an understanding of the function of CD56int NK 
cells, we analyzed surface molecules linked to NK cell cytotoxic-
ity, adhesion, and immune regulatory functions (e.g., chemokine 
and cytokine receptors) and compared the expression of KIRs, 
CD62L, NKG2A, CD127, CD117, CX3CR1, CD226, and CD57 
on all three NK subpopulations. The CD56dim population showed 
a higher expression of KIRs, whereas the CD56int and CD56bright 
population did not. However, not all KIRs applied within the 
mix were expressed with equal density (Figure 4). Regarding the 
homing receptor CD62L, the CD56int, and the CD56bright fraction 
showed an increased expression compared to CD56dim population. 
The expression of NKG2A was highest on CD56int and CD56bright 
cells but bipartite in CD56dim NK cells. CX3CR1 is involved 
in adhesion and migration of NK cells and to a small extent 
higher presented on CD56dim NK cells. As already described, we 
could also show that CD57 was only detectable on the CD56dim 
subpopulation. Low expression of CD127 (IL7α chain), CD117 
(c-Kit), and CD226 (DNAM-1) could be seen on all NK cell sub-
populations; however, CD56bright intend to have higher expression 
than CD56dim, whereas CD56int was always lying in between. In 
summary, the expression profiles of CD56int and CD56bright NK 
cells were nearly congruent, but differed to CD56dim cells in KIR, 
CD62L, NKG2A, CX3CR1, and CD57 expression (Figure 4).
influence of Viral infection Post-hscT on 
nK cell reconstitution
The immune reconstitution of NK cell subpopulations post-HSCT 
was analyzed in patients without events and patients suffering 
from ADV (n = 5), EBV (n = 5), and CMV infection (n = 8). 
Infection was detected by the routine analysis of DNA copies in 
peripheral blood. Patients with elevated viral load at the day of 
transplantation were excluded from the study, resulting in a cohort 
of patients with occurrence of a positive viral load between 30 and 
90 days post-HSCT. Interestingly, we observed a slight reduction 
in CD56 and CD16 expression in patients suffering from viral 
infection in between day 30 and day 60 post-HSCT measured 
by mean fluorescence intensity (Figure 5). After viral clearance 
in most patients, a considerable loss in absolute CD56dim NK cell 
count occurred followed by continued regeneration of CD56int 
NK cells, which was lower in patients without events post-HSCT 
on day 150 post-HSCT (Figure 5).
DiscUssiOn
Especially in the early phase following allogeneic HSCT, together 
with neutrophils, NK cells are the first line of immune defense. 
Their immune reconstitution is of crucial importance for 
transplantation outcome with special regard to the occurrence 
of GvHD and viral infections. In this project, we analyzed NK 
cell subpopulations in detail not only focusing on CD56bright and 
CD56dim cells but also the fraction in between those subsets. With 
regard to NK cell subpopulation development in young healthy 
FigUre 4 | immunophenotyping of cD56bright, cD56int, and cD56dim cells. Exemplary flow cytometric plots of natural killer (NK) cell subpopulations of a patient 
4 months post-hematopoietic stem cell transplantation (HSCT) with GvHD showing an almost equal distribution of CD56bright, CD56int, and CD56dim cells (a) and of a 
healthy child aged 3 years with mainly CD56dim cytotoxic NK cells (B). NK cell subpopulations were characterized in detail by flow cytometric measurement of 
surface antigen expression of several ligands involved in adhesion, chemotaxis, and cytotoxicity. Expression of the corresponding receptors on NK cells is shown by 
overlay plots with MFI on the x-axis of respective antigen in allocation to CD56bright (dark gray), CD56int (red) compared to CD56dim NK cells (light gray). CD56bright and 
CD56int NK cells show comparable receptor expression, but differ to CD56dim cells in KIR-, CD62L, NKG2A, CX3CR1, and CD57 expression (c).
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children, we found that it takes around 12 months until CD56bright, 
CD56int, and CD56dim NK cells of patients post-HSCT reach the 
50th percentile of age-matched reference range. Comparable 
results were published by Pical-Izard et al. describing that rapidly 
re-emerging NK cells remain immature for more than 6 months 
(8). Directly after HSCT we detected a highly increased frequency 
of CD56bright, whereas CD56int NK cells correspond to the reference 
range, but considerably expand within the first 3 months post-
HSCT. In contrast, CD56dim NK cells deserve around 8 months to 
enter the reference range. These results confirm the hypothesis of 
sequential development of NK cells with CD56int NK cells repre-
senting an intermediate state from CD56bright to CD56dim NK cells 
(14, 15). These CD56bright NK cells in peripheral blood are closely 
related to those NK cells populating secondary lymphoid tissues 
(16). Further evidence supporting this hypothesis was published 
by Freud et al. describing that the CD56bright subset is the major 
NK cell population that is derived early in vitro when CD34+ HPC 
are cultured in NK development supportive conditions, whereas 
CD56dim NK cells develop later (17). Furthermore, CD56bright NK 
cells display longer telomeres than the CD56dim NK cells, indicat-
ing lower proliferation capacity (6).
We further characterized all three NK cell subpopulations with 
the finding, that CD56int presented antigen expressions among 
CD56bright and CD56dim NK cells, even so CD56bright and CD56int 
NK cells showed rather equal expression profiles and seemed 
related more to CD56bright. However, differential expression of 
KIRs, CD62L, NKG2A, and CD57 was observed on CD56dim NK 
cells. This is in parallel to other findings describing an increased 
expression of NKG2A, the IL-7 receptor (CD127) and the lymph 
node homing receptor CCR7 on CD56bright cells (2, 5, 8, 18, 19) 
whereas CD56dim NK cells acquire KIR, NKG2C, and CD57 
expression (20).
FigUre 5 | Viral infections influencing natural killer (nK) cell reconstitution and nK marker expression density. Exemplary flow cytometric plots of a 
patient without events and patients suffering from adenovirus (ADV), Epstein–Barr virus (EBV), and cytomegalovirus (CMV) infection between 15 and 150 days 
post-HSCT. Patients with high viral load (e.g., ADV above 40,000 genome equivalent/ml and CMV above 90,000 IU/ml) or qualitatively confirmed EBV infection with 
disease onset between day 30 and day 60 were exemplarily presented. NK cells of patients suffering from viral infection showed a slight reduction in CD56 and 
CD16 receptor expression 90 days post-HSCT (frame). After 150 days post-HSCT, the NK cells of the patient without events consisted of a major population of 
CD56dim, a small amount of CD56bright and only few CD56int cells whereas patients after EBV and CMV infection showed a distinct population of CD56int NK cells 
again. Patients suffering from infections: ADV (n = 5), EBV (n = 5), CMV (n = 8).
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Promoted by the IL-15 rich cytokine milieu post-transplant, 
NK cells are known to be one of the first lymphocyte subpopula-
tion recovering post-HSCT (21). Therefore, NK cell reconstitu-
tion might be the basis for generating early prognostic markers 
regarding the occurrence of severe events and transplantation 
outcome. Kim et  al. published that NK cell counts after allo-
HSCT, especially on day 30, were predictive markers for GvHD, 
non-relapse mortality, and survival (22). Furthermore, there is 
evidence that the speed of NK cell reconstitution correlates with 
transplant outcome, suggesting their important role in the early 
period when specific T cell immunity is absent (7, 8). Our and 
other findings suggest that the monitoring of NK cell subsets in 
the early phase post-HSCT might provide first signs of aGvHD 
development (23). Interestingly, within the first 2  months 
post-HSCT patients without aGvHD or viral infections had 
significantly elevated levels of CD56bright NK cells compared to 
patients suffering from aGvHD. This might be an early prognos-
tic factor regarding GvHD development; however, it needs to 
be confirmed in a prospective study. Likewise results were also 
published by Kheav et al. showing an impaired reconstitution of 
CD56dim NK cells 3  months post-HSCT (24). We also found a 
comparable trend for NK cell regeneration in patients suffering 
from cGvHD, although not significant (data not shown). This 
might be explained by the fact, that for aGvHD analysis, only 
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patients suffering from GvHD grades III and IV were considered, 
whereas no differentiation was available regarding cGvHD (e.g., 
chronification of primary aGvHD grades I and II).
Literature is discordant whether steroids/immunosuppression 
have a negative impact on NK cell reconstitution. Giebel et  al. 
proposed that the use of steroids for GvHD prophylaxis negatively 
affects quantitative reconstitution of NK cells after allo-HSCT 
(25). Although, patients suffering from GvHD grades III and IV 
normally receive steroids in our transplantation unit, we did not 
see any significant differences in the quantitative reconstitution of 
absolute NK cell numbers. Interestingly, Wang et al. described that 
CSA suppresses the in vitro proliferation of NK cells, especially 
the CD56dimCD16+KIR+ NK cells, resulting in a relative increase 
in the number of immature CD56brightCD16−KIR− NK cells (26). 
This might also contribute to the delayed NK cell development 
in patients suffering from higher grade aGvHD that we observed 
within this study. However, this remains controversial as other 
studies analyzed the effect of CSA on NK cell function in short-
term cultures and their cytokine production without finding 
significant differences between NK cells with and without CSA 
treatment (27, 28).
In patients suffering from viral infection post-HSCT, we 
observed a slight reduction in CD56 and CD16 expression. 
Notably, other publications already described the existence of 
CD56−CD16+ NK cells (CD56negative) NK cells in viral infections 
(e.g., HIV, hepatitis C), where NK cells undergo numerous phe-
notypic and functional changes (29). This CD56negative subset has 
been associated with high HIV viral load and has been reported 
to have an impaired cytolytic function and cytokine production 
(30). This increase occurred primarily at the expense of CD56dim 
NK cells, whereas numbers of CD56bright NK cells remained stable 
(31). Furthermore, we observed a considerable loss in absolute 
CD56dim NK cells followed by continued regeneration of CD56int 
NK cells. Alteration of NK cells upon viral infection has already 
been shown by other research groups, for example Pical-Izard 
et al. showed that in patients being affected by CMV reactivation, 
NK cells showed lower degranulation and TNF-α production 
compared to patients without CMV reactivation post-HSCT (8). 
In addition, it was shown that CMV reactivation is followed by an 
increase in the proportion of NKG2C+ NK cells within 2–4 weeks, 
which persist for at least a year (32, 33).
In conclusion, only after around 12  months, NK cells post-
HSCT reconstitute to a distribution of the subpopulations 
CD56bright, CD56int, and CD56dim comparable to age-matched 
healthy controls. The expression profiles of CD56int and CD56bright 
NK cells resemble each other but differed in KIR, CD62L, 
NKG2A, CX3CR1, and CD57 expression to CD56dim NK cells. 
We observed elevated levels of CD56bright directly after and 
CD56int NK cells 3 months post-HSCT accompanied by reduced 
CD56dim NK cells supporting the hypothesis of sequential NK cell 
development. Furthermore, we analyzed alterations in NK cell 
development in patients with severe viral infections and GvHD. 
Following viral infection, there was a slight reduction in CD56 
and CD16 receptor expression followed by a considerable loss in 
absolute CD56dim NK cells and continued regeneration of CD56int 
NK cells. Most important, within the first 2 months, post-HSCT 
patients without severe events had significantly elevated levels of 
CD56bright NK cells compared to patients suffering from aGvHD. 
While first measurements performed as early as 15 days following 
HSCT revealed the most significant differences, clinical occur-
rence of aGvHD was observed in median on day 22 post-HSCT. 
Therefore, we recommend immunophenotyping of NK cell 
subpopulations directly following engraftment, which might be 
an early prognostic factor regarding GvHD development.
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